ADVENTRX Pharmaceuticals Gets Notice About Exelbine Print E-mail
By Staff and Wire Reports   
Wednesday, 06 October 2010 07:50
In what is seen as a positive step toward the future commercialization of Exelbine, ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. patent application entitled "Compositions for Delivering Highly Water Soluble Drugs."
"We remain on track to submit a New Drug Application for Exelbine this quarter," stated Brian M. Culley, Chief Executive Officer of ADVENTRX.

The patent claims are directed to formulations of vinorelbine bitartrate and provide protection for the Company's lead product candidate, ANX-530 (vinorelbine injectable emulsion), or Exelbine?.  The Notice of Allowance is the USPTO's official communication that the examination of the patent application has been successfully completed and that, upon timely payment of applicable fees, a patent will be issued. Once issued, before taking into account patent term extension, the patent will provide coverage for Exelbine until July 2024.

Back in March,the FDA accepted the proposed proprietary name Exelbine for the Company's product candidate ANX-530, which is manufactured at the Company's intended commercial manufacturing site. Exelbine is a novel emulsion formulation of a currently marketed chemotherapy drug. The company believes Exelbine may improve the safety of and have greater commercial potential than the currently marketed reference product.


The stock closed down slightly on Tuesday at $2.02.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter